Methodology and clinical utility of longitudinal <scp><i>UBA1</i></scp> tracking in <scp>VEXAS</scp> syndrome
Carmelo Gurnari(University of Rome Tor Vergata), Maria Teresa Voso(University of Rome Tor Vergata), Gregorio Maria Bergonzi(Vita-Salute San Raffaele University), Christian Thiede(Klinik und Poliklinik für Psychotherapie und Psychosomatik), Federica Pilo(University of Cagliari), Orietta Spinelli(Ospedale Papa Giovanni XXIII), Raffaella Greco(Vita-Salute San Raffaele University), Antonio Vitale(University of Siena), Elisa Diral(Vita-Salute San Raffaele University), Fabio Ciceri(San Antonio College), Giorgia Battipaglia(Federico II University Hospital), Lorenzo Dagna(Vita-Salute San Raffaele University), Elena Crisà(Candiolo Cancer Institute), Alessandro Tomelleri(Vita-Salute San Raffaele University), Corrado Campochiaro(Vita-Salute San Raffaele University), Federico Caroni(University of Siena), Alfonso Piciocchi(Fondazione Gimema Onlus), Cristina Papayannidis(University of Bologna), Marco Frigeni(Ospedale Papa Giovanni XXIII), Elisa Galossi(University of Rome Tor Vergata), Luca Cantarini(University of Siena), Mariadomenica Divona(San Antonio College), Fabrizio Pane(Ceinge Biotecnologie Avanzate (Italy)), Davide Firinu(University of Cagliari), Chiara Cardamone(University of Salerno), Arianna Savi(University of Turin), Katja Sockel(Innsbruck Medical University), Matteo Dragani(Ospedale Policlinico San Martino), Giulia Rivoli(Ospedale Policlinico San Martino), Erika Morsia(Marche Polytechnic University), Paola Triggianese(University of Rome Tor Vergata), Francesca Romano(Ospedale Antonio Cardarelli), Francesco D’Agostino(Casa Sollievo della Sofferenza), Annalisa Condorelli(Ospedale Papa Giovanni XXIII), Silvia Salmoiraghi(Ospedale Papa Giovanni XXIII), Eleonora Lumia(University of Rome Tor Vergata), Monica Bocchia(University of Siena), Elisa Casciani(University of Rome Tor Vergata), S Plebani(San Salvatore Hospital)
Cited by 10
Related Papers
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2018|1k
Gene Therapy for Immunodeficiency Due to Adenosine Deaminase Deficiency
|New England Journal of Medicine|2009|1k